<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Med</journal-id><journal-id journal-id-type="iso-abbrev">J Transl Med</journal-id><journal-title-group><journal-title>Journal of Translational Medicine</journal-title></journal-title-group><issn pub-type="epub">1479-5876</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3508816</article-id><article-id pub-id-type="publisher-id">1479-5876-10-S3-P3</article-id><article-id pub-id-type="doi">10.1186/1479-5876-10-S3-P3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4<sup>+</sup>CD45RO<sup>+</sup>CD25<sup>+</sup>CD127<sup>low</sup> regulatory T cells</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Walter</surname><given-names>Gina J</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Evans</surname><given-names>Hayley G</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Menon</surname><given-names>Bina</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Kirkham</surname><given-names>Bruce W</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Cope</surname><given-names>Andrew P</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Geissmann</surname><given-names>Frederic</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Taams</surname><given-names>Leonie S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Centre for Molecular and Cellular Biology of Inflammation, King&#x02019;s College London, London, UK</aff><aff id="I2"><label>2</label>Dept. Rheumatology, Guy&#x02019;s &#x00026; St Thomas&#x02019; NHS Foundation Trust, London, UK</aff><aff id="I3"><label>3</label>Academic Dept. Rheumatology, King&#x02019;s College London, London, UK</aff><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>28</day><month>11</month><year>2012</year></pub-date><volume>10</volume><issue>Suppl 3</issue><supplement><named-content content-type="supplement-title">7th European Workshop on Immune-Mediated Inflammatory Diseases</named-content><named-content content-type="supplement-editor">Timothy Radstake, Leonie Taams and Ola Winqvist</named-content></supplement><fpage>P3</fpage><lpage>P3</lpage><permissions><copyright-statement>Copyright &#x000a9;2012 Walter et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Walter et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.translational-medicine.com/content/10/S3/P3"/><conference><conf-date>28-30 November 2012</conf-date><conf-name>7th European Workshop on Immune-Mediated Inflammatory Diseases</conf-name><conf-loc>Noordwijk aan Zee, the Netherlands</conf-loc></conference></article-meta></front><body><sec><title>Introduction</title><p>Despite the high frequency of CD4<sup>+</sup> T cells with a regulatory phenotype (CD25<sup>+</sup>CD127<sup>low</sup>FoxP3<sup>+</sup>) in the joints of patients with rheumatoid arthritis (RA), inflammation persists. Regulatory T cells (Tregs) can be converted into pro-inflammatory IL-17-producing cells by inflammatory mediators, particularly IL-1&#x003b2;.</p></sec><sec><title>Aim</title><p>To investigate whether activated monocytes, which are abundantly present in the rheumatic joint and potent producers of IL-1&#x003b2;, induce pro-inflammatory cytokine expression in Tregs and whether this impairs Treg function.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>The presence and phenotype of CD4<sup>+</sup>CD45RO<sup>+</sup>CD25<sup>+</sup>CD127<sup>low</sup> T cells (memory Tregs) and CD14<sup>+</sup> monocytes in the peripheral blood (PB) and synovial fluid (SF) from patients with RA was investigated by flow cytometry. FACS-sorted memory Tregs from healthy controls were co-cultured with autologous <italic>in vitro</italic>-activated monocytes and anti-CD3 monoclonal antibody. Intracellular cytokine expression, phenotype and function were determined by flow cytometry, ELISA and proliferation assays.</p></sec><sec sec-type="results"><title>Results</title><p>Patients with RA showed higher frequencies of CD4<sup>+</sup>CD45RO<sup>+</sup>CD25<sup>+</sup>CD127<sup>low</sup> Tregs and activated CD14<sup>+</sup> monocytes in SF relative to PB. We demonstrate that activated monocytes induced an increase in the percentage of IL-17<sup>+</sup>, IFN&#x003b3;<sup>+</sup> and TNF-&#x003b1;<sup>+</sup>, but also IL-10<sup>+</sup> Tregs. Blocking and reconstitution experiments revealed that the observed increase in IL-17<sup>+</sup> and IFN&#x003b3;<sup>+</sup> Tregs was driven by monocyte-derived IL-1&#x003b2;, IL-6 and TNF-&#x003b1; and was mediated by both CD14<sup>+</sup>CD16<sup>-</sup> and CD14<sup>+</sup>CD16<sup>+</sup> monocyte subsets. Despite enhanced cytokine expression, cells maintained their CD25<sup>+</sup>FoxP3<sup>+</sup>CD39<sup>+</sup> Treg phenotype and showed enhanced capacity to suppress proliferation and IL-17 production by effector T cells.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Tregs exposed to a pro-inflammatory environment show increased suppressive activity.</p></sec></body></article>